No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis

Table 2 Diagnostic performance of the AD CSF biomarker panel compared to p-tau_rel

	AD panel		p-tau_rel	Aβ_1–42/p-tau_rel	p-tau₁₈₁/p-tau_rel
AD vs. non-AD	p-tau₁₈₁	0.883	0.619^$
AD vs. non-AD	Aβ_1–42/p-tau₁₈₁	0.860		0.657^$
AD vs. FTLD	p-tau₁₈₁	0.933	0.799^$
AD vs. FTLD	Aβ_1–42/p-tau₁₈₁	0.920		0.846^$
AD vs. DLB	t-tau	0.863	0.706^$
AD vs. DLB	Aβ_1–42/t-tau	0.855		0.747^$
AD vs. CJD	t-tau	0.896	0.978*
AD vs. CJD	p-tau₁₈₁/t-tau	1.000			1.000
AD vs. controls	t-tau	0.926	0.865
AD vs. controls	Aβ_1–42/t-tau	0.976		0.949
FTLD vs. controls	Aβ_1–42	0.679	0.588
FTLD vs. controls	p-tau₁₈₁/t-tau	0.827			0.695
DLB vs. controls	Aβ_1–42	0.747	0.717
DLB vs. controls	Aβ_1–42/p-tau₁₈₁	0.739		0.815
CJD vs. controls	t-tau	0.978	1.000
CJD vs. controls	Aβ_1–42/t-tau	1.000		1.000

The third column contains AUC values for the established single markers and biomarker ratios with the highest diagnostic value
Adjacent columns show AUC values of p-tau_rel and the equivalent ratio using p-tau_rel
Significant differences between AUC values (DeLong tests, p < 0.05) are marked by an asterisk (*) when diagnostic power is significantly higher with addition of p-tau_rel, and by a dollar sign (^$) when diagnostic power is significantly lower with addition of p-tau_rel
Aβ _1–42 amyloid-beta of 42 amino acids, AD Alzheimer’s disease, CJD Creutzfeldt-Jakob disease, CSF cerebrospinal fluid, DLB dementia with Lewy bodies, FTLD frontotemporal lobar degeneration, p-tau ₁₈₁ tau protein phosphorylated at threonine 181, p-tau _rel non-phosphorylated tau fraction, t-tau total tau protein

ISSN: 1758-9193